Infant RSV immunisation ‘highly effective’, real-world study confirms
The US data were published after WA announced a free immunisation program starting on 1 April.
The long-acting monoclonal antibody nirsevimab may be more effective in protecting infants against respiratory syncytial virus than clinical trial results would suggest, according to a real-world study.
The US Centers for Disease Control and Prevention (CDC) report showed that passive immunisation with nirsevimab (Beyfortus) was 90% effective in preventing respiratory syncytial virus (RSV)-related hospitalisations in infants versus an 81% efficacy rate seen in phase III trials.
